In the STEP 2 trial, adults with obesity or overweight plus type 2 diabetes lost a mean 9.6% of their body weight at 68 weeks with semaglutide 2.4 mg vs
What we eat and how we live directly impacts our health and well-being
An overview of all available calculators can be found on the peptide calculator hub
Emerging research suggests that GLP-1RAs may also be beneficial in treating conditions like obstructive sleep apnea (Malhotra et al., 2024), osteoarthritis (Bliddal et al., 2024), metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis with liver fibrosis (MASH) (Loomba et al., 2024), polycystic ovary syndrome (PCOS) (Szczesnowicz et al., 2023), Alzheimers disease (Liang et al., 2024), Parkinsons disease (Kalinderi et al., 2024), and addiction (Klausen et al., 2022)
Participants taking GLP-1RAs semaglutide or tirzepatide in a retrospective survey study, reported reduced drinking and binge drinking episodes 18